The triple negative cancer (TNBC) of the breast is a distinct tumor entity with histologic and molecular heterogeneity. Its main feature is the negative Predict Array Breast (cancer negative in the biomarkers for Estrogens, Progesterone and HER2). For triple negative breast cancer, hormone therapy or targeted anti-HER2 therapy are not options.

The pathologist uses an algorithm that combines

• Estimation of tumor’s morphology
• Estimation of tumor’s expression in specific immunohistochemical biomarkers (g. triple negative cancer group basal-like with BRCAness characteristics)
• Analysis of the molecular profile of the tumor, to check for the presence of mutations in specific genes. The panel contains up to 15 genes

Consult your Oncologist in order to get the best possible choice for you and a personalized treatment. Further personalization of exams are possible.

If your sample is not already in microDiagnostics Ltd Contact us immediately to arrange for safe and fast shipping to our laboratory.

You will also need to complete the Consent Form easily and quickly.

The number and type of mutations examined are updated through a dynamic process according to the current scientific research. It should therefore be recognized that there is a possibility that the list of genes in the order form may have changed (genes added or removed) when analyzing the sample in the laboratory.

The triple negative breast cancer (TNBC), is closed to non-hormonal therapy, or targeted therapy with anti-HER2 therapy. In these cases, non-specific chemotherapies are selected.

However, triple negative breast cancer can be subcategorized into the following 4 groups, combining morphology with immunophenotype and / or genotype:

• Basal-like triple negative cancer
  • Prone to treatment with PARP inhibitors or platinum
  • Determination of the Tumor as a Cancer with BRCAness Characteristics
• Claudin low mesenchymal triple negative cancer
  • Treatable with MET, FGFR and mTOR inhibitors
• Luminal Androgen Receptor Triple Negative Cancer
  • Prone to treatment with PIK3CA inhibitors and AR blockade
• Immunomodulatory triple negative cancer
  • Probably prone to immunotherapy

Consult your clinical doctor to personalize your treatment

The test is performed on the biopsy or surgical specimen (paraffinblock) that your histological examination was performed on.

If your sample is not already in microDiagnostics Ltd files Contact us immediately to arrange for safe and fast shipping to our laboratory.

You will also need to complete the Consent Form easily and quickly.

• In our vertical integrated Laboratory, we handle your sample in suchway as to minimize its unnecessary waste:
• The paraffin block is positioned if it is possible once in the microtome to obtain tissue sections from experienced histotechnologists.
• Tissue sections are sequentially acquired in such way as to ensure diagnosis and Immunohistochemical technics if required (diagnosis, prognosis)
• The Breast Signature is conducted on  Immunohistochemistry platforms in our laboratory at Leica Bond Max and Dako Autostainer Link 48, and also in a Next Generation Sequencing (NGS) platform.
• Assurance that tissue sections are preserved for further molecular testing in fully controlled storage conditions.